|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/23/10 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/23/25 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 572.55Cr | ||
| -0.46% | -0.35% | +19.17% | +70.44% | 4.89TCr | ||
| -2.55% | +3.68% | +55.51% | +121.02% | 4.14TCr | ||
| +0.13% | +0.41% | -3.73% | +18.55% | 1.24TCr | ||
| +0.44% | +6.82% | +25.32% | +86.64% | 1.25TCr | ||
| +1.15% | -0.38% | +30.98% | +136.36% | 908.38Cr | ||
| +1.95% | +9.12% | +25.38% | +40.22% | 752.55Cr | ||
| +0.31% | +5.45% | +40.87% | -12.57% | 713.71Cr | ||
| +0.69% | +1.44% | +11.34% | +187.29% | 673.41Cr | ||
| -1.22% | +4.46% | -25.04% | +29.64% | 588.22Cr | ||
| Average | +0.05% | +3,387.77% | +19.98% | +75.29% | 1.57TCr | |
| Weighted average by Cap. | -0.60% | +4,838.45% | +27.72% | +83.51% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















